↓ Skip to main content

Prostate cancer vaccines

Overview of attention for article published in Expert Review of Vaccines, January 2014

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
blogs
2 blogs

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Prostate cancer vaccines
Published in
Expert Review of Vaccines, January 2014
DOI 10.1586/erv.13.27
Pubmed ID
Authors
Abstract

In 2010, the US FDA approved the first therapeutic cancer vaccine for the treatment of castration refractory prostate cancer - sipuleucel-T. Prostate cancer is an ideal model for cancer vaccine development based on the ready demonstration of humoral and cellular immunity to a range of cancer antigens as well as often slow progression which means that patients who are otherwise well may have a radiologically evaluable minor progression, after conventional treatment and can undergo vaccine therapy over sufficient periods of time, so as to allow the generation of a robust antitumor response. The association of prostate cancer with one of the few serum cancer biomarkers in general use has also allowed assessment of response and risk stratification of patients. In this review, we will examine key aspects of the evolution of prostate cancer vaccines, which provides an accurate prototype for other cancers, and the challenges we face.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Bachelor 8 21%
Student > Master 6 15%
Researcher 6 15%
Student > Ph. D. Student 5 13%
Other 1 3%
Other 3 8%
Unknown 10 26%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 11 28%
Agricultural and Biological Sciences 7 18%
Immunology and Microbiology 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Sports and Recreations 2 5%
Other 4 10%
Unknown 10 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2018.
All research outputs
#2,236,782
of 28,815,917 outputs
Outputs from Expert Review of Vaccines
#193
of 1,774 outputs
Outputs of similar age
#23,012
of 331,698 outputs
Outputs of similar age from Expert Review of Vaccines
#58
of 730 outputs
Altmetric has tracked 28,815,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,774 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.4. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,698 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 730 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.